Ind Swift Laboratories Profile
Key Indicators
- Authorised Capital ₹ 100.00 Cr
- Paid Up Capital ₹ 59.09 Cr
- Company Age 30 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 4.70 Cr
- Satisfied Charges ₹ 5,103.76 Cr
- Revenue Growth 7.37%
- Profit Growth 885.10%
- Ebitda 12.55%
- Net Worth 36.56%
- Total Assets -38.22%
About Ind Swift Laboratories
Ind Swift Laboratories Limited (ISLL) is a leading Public Limited Indian Non-Government Company incorporated in India on 04 January 1995 and has a history of 30 years and two months. Its registered office is in Chandigarh, India.
It is listed on the Bombay Stock Exchange(BSE) under the ticker symbol 532305 and on the National Stock Exchange(NSE) under INDSWFTLAB.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 100.00 Cr and a paid-up capital of Rs 59.09 Cr.
The company currently has active open charges totaling ₹4.70 Cr. The company has closed loans amounting to ₹5,103.76 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Ind Swift Laboratories Limited India are Gagan Aggarwal as CFO and Pardeep Verma as Company Secretary. Himanshu Jain, Navrattan Munjal, Sahil Munjal, and Five other members serve as directors at the Company.
Company Details
- Location
Chandigarh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
L24232CH1995PLC015553
- Company No.
015553
- Stock Symbol
BSE : 532305 NSE : INDSWFTLAB
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
04 Jan 1995
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Listed
- ROC Code
Roc Chandigarh
Industry
Pharma
What products or services does Ind Swift Laboratories Limited offer?
Ind Swift Laboratories Limited offers a wide range of products and services, including Common Disease Medicines, Pharmaceutical Tablets, Pharma Ingredients & Raw Materials, API Intermediate, Thyroxine Sodium Tablets, Antipyretic and Analgesic API, Chemical Reagents & Catalysts, Organic Compounds, TB, Tumor & Cancer Drugs, Anti Cancer Injection.
Who are the key members and board of directors at Ind Swift Laboratories?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Navrattan Munjal  | Managing Director | 04-Jan-1995 | Current |
| Gagan Aggarwal | CFO | 29-Sep-2018 | Current |
| Pardeep Verma | Company Secretary | 01-Aug-1999 | Current |
Board Members (7)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sri Sharma | Director | 05-Jul-2017 | Current |
| Sahil Munjal | Whole-Time Director | 13-Feb-2020 | Current |
| Himanshu Jain | Whole-Time Director | 04-Jan-1995 | Current |
| Param Singh | Director | 27-Jun-2024 | Current |
| Rajinder Gupta | Director | 23-Jun-2021 | Current |
| Neerja Chathley | Director | 10-May-2019 | Current |
Financial Performance of Ind Swift Laboratories.
Ind Swift Laboratories Limited, for the financial year ended 2024, experienced modest growth in revenue, with a 7.37% increase. The company also saw a substantial improvement in profitability, with a 885.1% increase in profit. The company's net worth Soared by an impressive increase of 36.56%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ind Swift Laboratories?
In 2024, Ind Swift Laboratories had a promoter holding of 42.01% and a public holding of 58.00%. The company had 2 Subsidiaries. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Ind Swift LimitedHimanshu Jain, Navrattan Munjal and 1 more are mutual person
Indis Healthcare LlpHimanshu Jain is a mutual person
- Mjm Remedies Private Limited
Himanshu Jain and Navrattan Munjal are mutual person
- Fortune (India) Constructions Limited
Himanshu Jain, Sahil Munjal and 1 more are mutual person
- Essix Biosciences Limited
Himanshu Jain, Navrattan Munjal and 1 more are mutual person
- Nimbua Greenfield (Punjab) Association
Navrattan Munjal is a mutual person
Charges (Loans)
Open Charges
₹4.70 Cr
Satisfied Charges
₹5,103.76 Cr
Charges Breakdown by Lending Institutions
- Industrial Investment Bank Of India : 3.00 Cr
- Axis Bank Limited : 1.70 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 Aug 2023 | Axis Bank Limited | ₹1.70 Cr | Open |
| 11 Sep 2003 | Industrial Investment Bank Of India | ₹3.00 Cr | Open |
| 21 Jun 2019 | Idbi Trusteeship Services Limited | ₹808.83 Cr | Satisfied |
| 05 Sep 2018 | Others | ₹75.44 Cr | Satisfied |
| 05 Sep 2018 | Others | ₹424.50 Cr | Satisfied |
How Many Employees Work at Ind Swift Laboratories?
Unlock and access historical data on people associated with Ind Swift Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ind Swift Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ind Swift Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Latest Updates, News, and FAQs on Ind Swift Laboratories
Recent activity within the organization
- Annual General Meeting
Ind Swift Laboratories Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records.
- Director Appointment
Param Bir Singh was appointed as a Director was appointed as a Director on 27 Jun 2024 & has been associated with this company since 8 months 6 days .
- Charges
A charge registered on 21 Jun 2019 via Charge ID 100270484 with Idbi Trusteeship Services Limited was fully satisfied on 12 Apr 2024.
- Charges
A charge registered on 05 Sep 2018 via Charge ID 100214960 with Others was fully satisfied on 05 Apr 2024.
- Charges
A charge registered on 05 Sep 2018 via Charge ID 100215281 with Others was fully satisfied on 05 Apr 2024.
- Balance Sheet
Ind Swift Laboratories Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Chandigarh.
Recent News, Updates & Announcement
- lndiaRF to acquire API, CRAMS business of Ind-Swift Labs.
IndiaRF will acquire the active pharmaceutical ingredients (API) and contract research and manufacturing services (CRAMS) business of Ind-Swift Labs for a consideration of Rs 1,650 crore. ET first reported on this transaction on July 21 this year. The acquisition will be done through Synthimed Labs, a portfolio company of India Resurgence Fund.
- India resurgence fund in talks to acquire Ind-Swift's API business.
Earlier in July 2021, Ind-Swift Laboratories had agreed to sell its API business to PI Industries on a slump sale basis, for ₹1,530 crore. However, the deal had been terminated by PI Industries in November 2021. Incorporated in 1995, IISL is engaged in the manufacturing of APIs, advanced intermediates and providing Contract Research and Manufacturing Services (CRAMS). The company has three manufacturing facilities- two in Dera Bassi (including research facility), Punjab and one in Samba, Jammu & Kashmir..
Frequently asked questions
What is the Incorporation or founding date of Ind Swift Laboratories Limited?
Ind Swift Laboratories Limited was incorporated on 04 Jan 1995.
What is authorized share capital and paid-up capital of Ind Swift Laboratories Limited?
The authorized share capital of Ind Swift Laboratories Limited is ₹ 100.00 Cr and paid-up capital is ₹ 59.09 Cr.
Who are the current board members & directors of Ind Swift Laboratories Limited?
Currently 10 directors are associated with Ind Swift Laboratories Limited.
- Himanshu Jain
- Navrattan Munjal
- Sahil Munjal
- Sri Prakash Sharma
- Param Bir Singh
- Gagan Aggarwal
- Pardeep Verma
- Rajinder Kumar Gupta
- Neerja Chathley
- Rishav Mehta
What is the registered address of Ind Swift Laboratories Limited?
As per Ministry of Corporate Affairs (Mca), the registered address of Ind Swift Laboratories Limited is Sco 850 Shivalik Enclave Nac, Manimajra India, Chandigarh, 160101.
What is the corporate identification number (CIN) and company number of Ind Swift Laboratories Limited?
The corporate identification number (CIN) of Ind Swift Laboratories Limited is L24232CH1995PLC015553 and the company number is 015553 as per Ministry of Corporate Affairs (MCA).
Is Ind Swift Laboratories Limited registered with any stock exchange in India?
Yes, Ind Swift Laboratories Limited is registered on Bombay Stock Exchange (BSE) and National Stock Exchange (NSE): INDSWFTLAB.
What is the official website of Ind Swift Laboratories Limited?
The Official website of Ind Swift Laboratories Limited is https://www.indswiftlabs.com
What has been the recent revenue trend for Ind Swift Laboratories Limited?
According to the financial reports for the fiscal year 2024, the revenue trend for Ind Swift Laboratories Limited has risen by 7.37%.
What change has been observed in the net worth of Ind Swift Laboratories Limited, and by what percentage?
The financial reports for the fiscal year 2024 indicates that The net worth of Ind Swift Laboratories Limited has experienced an upsurge of 36.56%.
What are the total open charges for Ind Swift Laboratories Limited?
As per the financial statements for fiscal Year 2024, The total open charges for Ind Swift Laboratories Limited amount to ₹ 4.70 Cr.
When was the last Balance Sheet of Ind Swift Laboratories Limited filed with the ROC?
The most recent Balance Sheet for Ind Swift Laboratories Limited was filed with the ROC on 31 Mar 2024.
People also Viewed
Poonam MainiDirector
Narinder SinghDirector
Atul SaxenaNominee DirectorGM
Gopal MunjalDirectorSM
Sanjeev MehtaDirectorKN
Kotakkatteri NambiarDirectorVM
Vishav MehtaManaging DirectorJK
Jatendar KakkarDirector
Similar Companies Based on API Manufacturers
Mylan Laboratories Limited Hyderabad, Telangana, India
Sun Pharmaceutical Industries Limited Vadodara, Gujarat, India
Msn Laboratories Private Limited Rangareddy, Telangana, India
Lupin Limited Mumbai, Maharashtra, India
Ipca Laboratories Limited Mumbai, Maharashtra, India
Divi's Laboratories Limited Rangareddy, Telangana, India
Hetero Labs Limited Rangareddy, Telangana, India
Glenmark Pharmaceuticals Limited Mumbai, Maharashtra, India